Although the incidence of prostate cancer decreased following the 2008 and 2012 United States Preventive Services Taskforce recommendations against prostate specific antigen–based screening,24,25 it does not fully explain the decrease in PBT use targeted to the prostate between 2011 and 2014. This evidence concerns the gene KLK3 and Familial prostate cancer.